Review of epigenetic dysregulation in nasopharyngeal carcinoma management

This publication is a narrative review focusing on epigenetic dysregulation in nasopharyngeal carcinoma. The scope covers aberrant DNA and RNA methylation, histone modifications, and non-coding RNA networks as potential targets for understanding disease progression. The authors do not report specific sample sizes or adverse events because this is a review rather than a primary trial.

The key arguments synthesized by the authors suggest that clarifying these epigenetic insights could support biomarker-guided and precision-oriented management of nasopharyngeal carcinoma. However, the review highlights several critical gaps. These include tumor heterogeneity, off-target effects, and insufficient validation of the proposed mechanisms.

The authors caution that practice relevance must be interpreted with restraint given these limitations. No specific dosages, p-values, or confidence intervals are provided because the source does not contain trial-level data. Clinicians should consider these epigenetic factors as emerging concepts rather than established clinical standards. The review does not report serious adverse events or discontinuations because such data are not applicable to this type of publication.